These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 3287388

  • 1. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
    Labrie F, Dupont A, Cusan L, Bélanger A, Giguère M, Labrie C, Lacourcière Y, Monfette G, Emond J.
    Prog Clin Biol Res; 1988; 262():11-63. PubMed ID: 3287388
    [No Abstract] [Full Text] [Related]

  • 2. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P.
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [Abstract] [Full Text] [Related]

  • 3. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Oct; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
    Dupont A, Cusan L, Gomez JL, Koutsilieris M, Suburu R, Emond J, Labrie F.
    Br J Urol; 1993 Nov; 72(5 Pt 1):629-34. PubMed ID: 10071551
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
    Dupont A, Labrie F, Giguere M, Borsanyi JP, Lacourciere Y, Bergeron N, Cusan L, Belanger A, Emond J.
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):659-66. PubMed ID: 3289945
    [Abstract] [Full Text] [Related]

  • 7. Flutamide for prostate cancer.
    Med Lett Drugs Ther; 1989 Jul 28; 31(797):72. PubMed ID: 2501635
    [No Abstract] [Full Text] [Related]

  • 8. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar 28; 3(3):135. PubMed ID: 2518157
    [No Abstract] [Full Text] [Related]

  • 9. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, Monfette G.
    J Steroid Biochem; 1988 Mar 28; 30(1-6):107-17. PubMed ID: 3290578
    [Abstract] [Full Text] [Related]

  • 10. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H, Makino T, Kumasaka F, Shida K.
    Hinyokika Kiyo; 1984 Apr 28; 30(4):545-60. PubMed ID: 6435416
    [Abstract] [Full Text] [Related]

  • 11. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
    Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B.
    Clin Invest Med; 1993 Dec 28; 16(6):499-509. PubMed ID: 8013155
    [Abstract] [Full Text] [Related]

  • 12. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.
    J Steroid Biochem; 1986 Nov 28; 25(5B):877-83. PubMed ID: 3100871
    [Abstract] [Full Text] [Related]

  • 13. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D, Dubé D, Bélanger A, Labrie F.
    Mol Cell Endocrinol; 1989 Dec 28; 67(2-3):131-8. PubMed ID: 2693158
    [Abstract] [Full Text] [Related]

  • 14. Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
    Chodoff L.
    Mt Sinai J Med; 1990 May 28; 57(3):171-3. PubMed ID: 2115128
    [No Abstract] [Full Text] [Related]

  • 15. Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.
    Schally AV, Redding TW, Paz-Bouza JI, Comaru-Schally AM, Mathe G.
    Prog Clin Biol Res; 1987 May 28; 243A():173-97. PubMed ID: 2889215
    [No Abstract] [Full Text] [Related]

  • 16. Mechanism of action and pure antiandrogenic properties of flutamide.
    Labrie F.
    Cancer; 1993 Dec 15; 72(12 Suppl):3816-27. PubMed ID: 8252497
    [Abstract] [Full Text] [Related]

  • 17. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
    Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F.
    Am J Med; 1992 May 15; 92(5):465-70. PubMed ID: 1349790
    [Abstract] [Full Text] [Related]

  • 18. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
    Tarle M, Ahel MZ, Kovacić K.
    Anticancer Res; 2002 May 15; 22(4):2525-9. PubMed ID: 12174956
    [Abstract] [Full Text] [Related]

  • 19. Current treatment of advanced prostate cancer.
    Ismail M, Gomella LG.
    Tech Urol; 1997 May 15; 3(1):16-24. PubMed ID: 9170220
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 May 15; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.